Expert consensus: Renal denervation for the treatment of arterial hypertension

Archives of Cardiovascular Diseases

Volumn 105, Issue 6-7, 2012, Pages 386-393

  Pathaka, Atul ^a   Girerd, Xavier ^b   Azizi, Michel ^c   Benamerd, Hakim ^d   Halimie, Jean Michel ^e   Lantelmef, Pierre ^f   Lefèvreg, Thierry ^g   Sapoval, Marc ^c  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HEP la Roseraie   (France)

^e UNIVERSITÉ DE TOURS   (France)

^f UNIVERSITÉ LYON 1   (France)

^g Hospital Privé Jacques Cartier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; HORMONE RECEPTOR BLOCKING AGENT; LOOP DIURETIC AGENT; SPIRONOLACTONE;

AMBULATORY MONITORING; ARTERY CATHETERIZATION; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; FALSE ANEURYSM; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY ARTERY; KIDNEY DENERVATION; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PHYSICIAN; RADIOFREQUENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATHETER ABLATION; CONSENSUS; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; KIDNEY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84864115374     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.03.005     Document Type: Article

References (18)

1. Godet-Mardirossian H, Girerd X, Vernay M, et al. Patterns of hypertension management in France (ENNS 2006-2007). Eur J Prev Cardiol 2012;19:213-20.
2. Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ 2011;343:d4891.
3. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011;57:1076-80.
4. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635-42.
5. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-26.
6. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;58:765-73.
7. Krum H, Schlaich M, Sobotka P, et al. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur Heart J 2011;32:537-44.
8. Joyner MJ, Charkoudian N, Wallin BG. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications. Hypertension 2010;56:10-6.
9. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010;298:R245-53.
10. Katholi RE, Whitlow PL, Winternitz SR, et al. Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension. Hypertension 1982;4:166-74.
11. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002;106:1974-9.
12. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension 2003;41:621-4.
13. Evelyn KA, Singh MM, Chapman WP, et al. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med 1960;28:188-221.
14. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953;1:403-8.
15. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953;152:1501-4.
16. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9.
17. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
18. Simplicity HTN-1 Investigators 2011. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-7.